Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma has announced a conference call scheduled for November 10, 2022, at 4 pm CET (10 am ET). The call will follow the release of the third quarter results for 2022. Key executives, including Adam Steensberg and Henriette Wennicke, will present insights and answer questions. Zealand Pharma specializes in peptide-based medicines, with over 10 drug candidates in clinical development. The event will be accessible via registration and will also be available as a recording on Zealand’s Investor website.
Zealand Pharma (Nasdaq: ZEAL) announced its presentations at the Obesity Society Annual Meeting in San Diego, showcasing significant clinical and preclinical research. Key highlights include data from a Phase 2 trial of the GCGR/GLP-1R dual agonist BI 456906, which showed body weight reductions of up to 9% in patients with type 2 diabetes after 16 weeks. The company will also present preclinical results on its peptide candidates, including dapiglutide, ZP8396, and ZP6590, all demonstrating potential for obesity treatment.
Zealand Pharma A/S announces its total number of shares and voting rights as of October 31, 2022, in compliance with the Danish Capital Markets Act. Following a recent increase in share capital due to a private placement of 4,975,000 new shares, Zealand now has a total of 51,513,186 shares, which equals the same number for voting rights and share capital. This reflects Zealand's ongoing focus on developing innovative peptide-based medicines, with several drug candidates advancing in clinical development.
Zealand Pharma (Nasdaq: ZEAL) received a notification from major shareholder Polar Capital on October 11, 2022. As of October 10, Polar Capital holds 5,930,317 shares, representing 11.51% of Zealand's total share capital and voting rights. Zealand Pharma is a biotechnology company focused on developing innovative peptide-based medicines, with a successful portfolio of drug candidates, including two on the market and three in late-stage development.
Zealand Pharma (Nasdaq: ZEAL) has announced a significant shareholder update on October 10, 2022. Van Herk Investments B.V. now holds 7,630,244 shares, representing 14.81% of Zealand’s total share capital and voting rights as of October 7, 2022. The announcement details the ownership structure, indicating that Van Herk Investments is ultimately controlled by Mr. Adrianus van Herk. Zealand Pharma continues to focus on developing peptide-based medicines, with multiple drug candidates in clinical development.
Zealand Pharma announced the registration of a capital increase through the issuance of 4,975,000 new shares, raising approximately DKK 786 million. Following this increase, Zealand’s share capital will reach DKK 51,513,186 with a nominal value of DKK 1 per share. The new shares will be admitted for trading on Nasdaq Copenhagen on 10 October 2022. This move aims to support the company's growth in developing innovative peptide-based medicines. The shares rank equally with existing shares concerning voting and dividend rights.
Zealand Pharma announced the completion of a directed issue and private placement of 4,975,000 new ordinary shares at a subscription price of DKK 158 each, raising approximately DKK 786 million. The offering targets institutional and professional investors and aims to support the development of Zealand's peptide-based therapeutics, particularly the Phase 3 trial of glepaglutide for Short Bowel Syndrome. The New Shares are expected to be listed on Nasdaq Copenhagen on October 10, 2022, with a 90-day lock-up period for management. The funds are projected to extend the company's cash runway until Q2 2024.
Zealand Pharma has announced the launch of a private placement of approximately 4.5 million new shares aimed at institutional and professional investors. The net proceeds will fund the ongoing development of its peptide-based therapeutics pipeline, particularly supporting the Phase 3 EASE clinical program for glepaglutide, with cash runway expected until Q2 2024. The offering is being conducted through an accelerated bookbuilding process, and the new shares are expected to be listed on Nasdaq Copenhagen by October 10, 2022.
Zealand Pharma announced the total number of shares and voting rights as of September 30, 2022, following changes in its share capital due to employee warrants exercised. The total number of shares is 46,538,186, which reflects the nominal value of DKK 1 each. This disclosure aligns with the Danish Capital Markets Act requirements for transparency in shareholder equity. Zealand Pharma focuses on developing peptide-based medicines and maintains partnerships with Boehringer Ingelheim and AstraZeneca.
